SYNB1020

Phase 1/2Terminated

1 views this week 0 watching💤 Quiet

Interest: 14/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cirrhosis

Conditions

Cirrhosis

Trial Timeline

Mar 19, 2018 → Jul 19, 2019

NCT ID

NCT03447730

About SYNB1020

SYNB1020 is a phase 1/2 stage product being developed by Synlogic for Cirrhosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03447730. Target conditions include Cirrhosis.

What happened to similar drugs?

6 of 11 similar drugs in Cirrhosis were approved

Approved (6) Terminated (0) Active (5)

✅Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved

✅Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)NovartisApproved

✅Telbivudine + Enecavir + AdefovirNovartisApproved

✅abataceptBristol Myers SquibbApproved

✅losartan (drug)LundbeckApproved

✅AlbuminGrifolsApproved

🔄peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03447730	Phase 1/2	Terminated	Mar 19, 2018	Jul 19, 2019	Cirrhosis

Competing Products

20 competing products in Cirrhosis

See all competitors

Product	Company	Stage	Hype Score
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin	Chugai Pharmaceutical	Phase 3	40
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)	Shionogi	Phase 2	35
Mesenchymal Stem Cell	Rohto Pharmaceutical	Pre-clinical	26
Bumetanide + Furosemide	Johnson & Johnson	Phase 3	47
Mesenchymal stem cell	Rohto Pharmaceutical	Phase 1/2	32
Zibotentan	AstraZeneca	Phase 1	29
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozin	AstraZeneca	Phase 2	27
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin	AstraZeneca	Phase 2	35
ARQ 197	Merck	Phase 1	29
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV	Merck	Approved	39
Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)	Novartis	Approved	43
Telbivudine + Enecavir + Adefovir	Novartis	Approved	39
Serelaxin + Placebo	Novartis	Phase 2	35
Terlipressin acetate + Serelaxin (RLX030)	Novartis	Phase 2	35
Pasireotide	Novartis	Phase 1	29
HPN-100 + Placebo	Amgen	Phase 2	35
Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mg	Gilead Sciences	Phase 2	27
TDF/FTC/LPV/r + Placebo	Gilead Sciences	Pre-clinical	18
MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg Capsule	Gilead Sciences	Phase 2	35
Seladelpar 5 mg Capsule + Seladelpar 10 mg Capsule	Gilead Sciences	Phase 3	44